Characterization of human liver cytochrome P-450 enzymes involved in the O-demethylation of a new P-glycoprotein inhibitor HM-30181

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 70, Issue 15-16, 2007, Pages 1356-1364

  Paek, In Bok ^a,b   Kim, Sung Yeon ^a   Kim, Maeng Sup ^b   Kim, John ^b   Lee, Gwansun ^b   Lee, Hye Suk ^a  

^a Wonkwang University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 O NOR 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL]AMIDE; 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL]AMIDE; 5 O NOR 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL]AMIDE; 6 O NOR 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL]AMIDE; 7 O NOR 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL]AMIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLYCOPROTEIN P INHIBITOR; HM 30181; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BENZOPYRANS; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HUMANS; ISOQUINOLINES; MICROSOMES, LIVER; OXIDOREDUCTASES, O-DEMETHYLATING; P-GLYCOPROTEIN; TETRAZOLES;

EID: 34547165126     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390701434307     Document Type: Conference Paper

References (33)

1. Abu-Quare, A. W., Elmasry, E., and Abou-Donia, M. B. 2003. A role for Pglycoprotein in environmental toxicology. J. Toxicol. Environ. Health B 6:279-288.
2. Bardelmeijer, H. A., Ouwehand, M., Beijnen, J. H., Schellens, J. H. M., and van Tellingen, O. 2004. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest. New Drugs 22:219-229.
3. Baldwin, S. J., Bloomer, J. C., Smith, G. J., Ayrton, A. D., Clarke, S. E., and Chenery, R. J. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
4. Dierks, E. A., Stams, K. R., Lim, H. K., Cornelius, G., Zhang, H., and Ball, S. E. 2001. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos. 29:23-29.
5. Ford, J. M., 1996. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. Eur. J. Cancer 32A:991-1001.
6. Fracasso, P. M., Goldstein, L. J., de Alwis, D. P., Rader, J. S., Arquette, M. A., Goodner, S. A., Wright, L. P., Fears, C. L., Gazak, R. J., Andre, V. A. M., Burgess, M. F., Slapak, C. A., and Schellens, J. H. M. 2004. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin. Cancer Res. 10:7220-7228.
7. Gottesman, M. M., Fojo, T., and Bates, S. E. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Natl. Rev. Cancer 2:48-58.
8. Lanning, C. L., Fine, R. L., Sachs, C. W., Rao, U. S., Corcoran, J. J., and Abou-Donia, M. B. 1996. Chlorpyrifos oxon interacts with the mammalian multidrug resistance protein, P-glycoprotein. J. Toxicol. Environ. Health 47:395-407.
9. Lehne, G. 2000. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr. Drug Targets 1:85-99.
10. Lillibridge, J. H., Liang, B. H., Kerr, B. M., Webber, S., Quart, B., Shetty, B., and Lee, C. A. 1998. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab. Dispos. 26:609-616.
11. Newton, D. J., Wang, R. W., and Lu, A. Y. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23:154-158.
12. Paek, I. B., Ji, H. Y., Kim, M. S., Lee, K. S., and Lee, H. S. 2006a. Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry. J. Sep. Sci. 29:628-634.
13. Paek, I. B., Ji, H. Y., Kim, M. S., Lee, K. S., and Lee, H. S. 2006b. Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/electrospray mass spectrometry. Rapid Comm. Mass Spectrom. 20:1457-1462.
14. Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F.W., Wong, F., Blumenschein, G., Fleming, D. R., Rouzier, R., Boniface, G., and Hortobagyi, G. N. 2005. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682-691.
15. Raderer, M. and Scheithauer, W. 1993. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72:3553-3563.
16. Raspollini, M. R., Pinzani, P., Pazzagli, M., Baroni, G., Taddei, A., Amunni, G., Villanucci, A., and Taddei, G. L. 2002. Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay. J. Chemother. 14:518-525.
17. Richter, T., Schwab, M., Eichelbaum, M., and Znager, U. M. 2005. Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem. Pharmacol. 69:517-524.
18. Sandler, A., Gordon, M., de Alwis D. P., Pouliquen, I., Green, L., Marder, P., Chaudhary, A., Fife, K., Battiato, L., Sweeney, C., Jordan, C., Burgess, M., and Slapak, C. A. 2004. A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin. Cancer Res. 10:3265-3272.
19. Sesardic, D., Boobis, A. R., Murray, B. P., Murray, S., Segura, J., de la Torre, R., and Davies, D. S. 1990. Furafylline is a potent and selective inhibitor of cytochrme P450IA2 in man. Br. J. Clin. Pharmacol. 29:651-663.
20. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-423.
21. Sikic, B. I. 1997. Pharmacologic approaches to reversing multidrug resistance. Semin. Hematol. 34(4 suppl. 5):40-47.
22. Sparreboom, A., and Nooter, K. 2000. Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist. Update 3:357-363.
23. Suzuki, H., Kneller, M. B., Haining, R. L., Trager, W. F., and Rettie, A. E. 2002. (+)-N-3-Benzylnirvanol and (-)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metab. Dispos. 30:235-239.
24. Thomas, H., and Coley, H. M. 2003. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10:159-165.
25. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Duan, S. X., Wright, C. E., Harmatz, J. S., and Shader, R. I. 1996. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. 36:783-791.
26. von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Duan, S. X., Fogelman, S. M., Daily, J. P., Harmatz, J. S., and Shader, R. I. 1998. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J. Clin. Pharmacol. 38:106-111.
27. Walker, J., Martin, C., and Callaghan, R. 2004. Inhibition of P-glycoprotein function by XR-9576 in a solid tumor model can restore anticancer drug efficacy. Eur. J. Cancer 40:594-605.
28. Walsky, R. L., Obach, R. S., Gaman, E. A., Gleeson, J. P. R., and Protor, W. R. 2005. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab. Dispos. 33:413-418.
29. Wang, J. S., Wen, X., Backman, J. T., Taavitsainen, P., Neubonnen, P. J., and Kivisto, K. T. 1999. Midazolam α-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol. Toxicol. 85:157-161.
30. Watkins, P. B., Wrighton, S. A., Mauel, P., Schuets, E. G., Mendezpicon, G., Parker, G. A., and Guzelian, P. S. 1985. Identification of an inducible form of cytochrome P-450 in human liver. Proc. Nat. Acad. Sci. USA 82:6310-6314.
31. Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., and Vandenbranden, M. 1990. Studies on the expression and metabolic capabilities of human liver cytochrome P-450 IIIA4 (HLp 3). Mol. Pharmacol. 38:207-213.
32. Wrighton, S. A., and Thummel, K. E. 2000. CYP3A. In Metabolic drug interactions, eds. R. H. Levy, K. E. Thummel, W. F. Trager, P. D. Hansten, and M. Eichelbaum pp. 115-133. Philadelphia: Lippincott Williams & Wilkins.
33. Yun, C. H., Shimada, T., and Guengerich, F. P. 1991. Purification and characterization of human liver microsomal cytochrome P450 2A6. Mol. Pharmacol. 40:679-685.